Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-10-2019 | Molecular Imaging | Editorial

Molecular imaging of impulse control disorders in Parkinson’s disease

Authors: Joonas Majuri, Juho Joutsa

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2019

Excerpt

Impulse control disorders (ICDs) affect approximately one seventh of patients with Parkinson’s disease (PD) [1]. Common ICDs include gambling disorder, hypersexuality, compulsive shopping, and binge eating. These disorders have been strongly linked to dopamine replacement therapy and, especially gambling disorder, share many clinical features with substance addictions [1, 2]. However, not all patients develop ICDs with dopamine replacement therapy, but the reasons for this and the neurobiological mechanisms underlying ICDs are still relatively poorly understood. …

Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67:589–95. https://doi.org/10.1001/archneurol.2010.65.CrossRefPubMed

Yau YH, Potenza MN. Gambling disorder and other behavioral addictions: recognition and treatment. Harv Rev Psychiatry. 2015;23:134–46. https://doi.org/10.1097/HRP.0000000000000051.CrossRefPubMedPubMedCentral

Navalpotro-Gomez I, Dacosta-Aguayo R, Molinet-Dronda F, Martin-Bastida A, Botas-Peñin A, Jimenez-Urbieta H, et al. Nigrostriatal dopamine transporter availability, and its metabolic and clinical correlates in Parkinson’s disease patients with impulse control disorders. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-019-04396-3.

Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3:760–73. https://doi.org/10.1016/S2215-0366(16)00104-8.CrossRefPubMedPubMedCentral

Cilia R, Ko JH, Cho SS, van Eimeren T, Marotta G, Pellecchia G, et al. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson’s disease and pathological gambling. Neurobiol Dis. 2010;39:98–104. https://doi.org/10.1016/j.nbd.2010.03.013.CrossRefPubMed

Lee JY, Seo SH, Kim YK, Yoo HB, Kim YE, Song IC, et al. Extrastriatal dopaminergic changes in Parkinson’s disease patients with impulse control disorders. J Neurol Neurosurg Psychiatry. 2014;85:23–30. https://doi.org/10.1136/jnnp-2013-305549.CrossRefPubMed

Voon V, Rizos A, Chakravartty R, Mulholland N, Robinson S, Howell NA, et al. Impulse control disorders in Parkinson’s disease: decreased striatal dopamine transporter levels. J Neurol Neurosurg Psychiatry. 2014;85:148–52. https://doi.org/10.1136/jnnp-2013-305395.CrossRefPubMed

Vriend C, Nordbeck AH, Booij J, van der Werf YD, Pattij T, Voorn P, et al. Reduced dopamine transporter binding predates impulse control disorders in Parkinson’s disease. Mov Disord. 2014;29:904–11. https://doi.org/10.1002/mds.25886.CrossRefPubMed

Premi E, Pilotto A, Garibotto V, Bigni B, Turrone R, Alberici A, et al. Impulse control disorder in PD: a lateralized monoaminergic frontostriatal disconnection syndrome? Parkinsonism Relat Disord. 2016;30:62–6. https://doi.org/10.1016/j.parkreldis.2016.05.028.CrossRefPubMed

10.

Smith KM, Xie SX, Weintraub D. Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. J Neurol Neurosurg Psychiatry. 2016;87:864–70. https://doi.org/10.1136/jnnp-2015-311827.CrossRefPubMed

11.

Steeves TD, Miyasaki J, Zurowski M, Lang AE, Pellecchia G, Van Eimeren T, et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain. 2009;132:1376–85. https://doi.org/10.1093/brain/awp054.CrossRefPubMedPubMedCentral

12.

O’Sullivan SS, Wu K, Politis M, Lawrence AD, Evans AH, Bose SK, et al. Cue-induced striatal dopamine release in Parkinson’s disease-associated impulsive-compulsive behaviours. Brain. 2011;134:969–78. https://doi.org/10.1093/brain/awr003.CrossRefPubMed

13.

Ray NJ, Miyasaki JM, Zurowski M, Ko JH, Cho SS, Pellecchia G, et al. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson’s patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. Neurobiol Dis. 2012;48:519–25. https://doi.org/10.1016/j.nbd.2012.06.021.CrossRefPubMedPubMedCentral

14.

Payer DE, Guttman M, Kish SJ, Tong J, Strafella A, Zack M, et al. [¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson’s disease with impulse control disorders. Mov Disord. 2015;30:160–6. https://doi.org/10.1002/mds.26135. CrossRefPubMed

15.

Wu K, Politis M, O’Sullivan SS, Lawrence AD, Warsi S, Bose S, et al. Single versus multiple impulse control disorders in Parkinson’s disease: an ¹¹C-raclopride positron emission tomography study of reward cue-evoked striatal dopamine release. J Neurol. 2015;262:1504–14. https://doi.org/10.1007/s00415-015-7722-7.CrossRefPubMed

16.

Stark AJ, Smith CT, Lin YC, Petersen KJ, Trujillo P, van Wouwe NC, et al. Nigrostriatal and mesolimbic D2/3 receptor expression in Parkinson’s disease patients with compulsive reward-driven behaviors. J Neurosci. 2018;38:3230–9. https://doi.org/10.1523/JNEUROSCI.3082-17.2018.CrossRefPubMedPubMedCentral

17.

Saari L, Kivinen K, Gardberg M, Joutsa J, Noponen T, Kaasinen V. Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease. Neurology. 2017;88:1461–7. https://doi.org/10.1212/WNL.0000000000003810.CrossRefPubMed

18.

Honkanen EA, Saari L, Orte K, Gardberg M, Noponen T, Joutsa J, et al. No link between striatal dopaminergic axons and dopamine transporter imaging in Parkinson’s disease. Mov Disord. 2019. https://doi.org/10.1002/mds.27777.

19.

Joutsa J, Martikainen K, Niemelä S, Johansson J, Forsback S, Rinne JO, et al. Increased medial orbitofrontal [18F]fluorodopa uptake in Parkinsonian impulse control disorders. Mov Disord. 2012;27:778–82. https://doi.org/10.1002/mds.24941.CrossRefPubMed

20.

Joutsa J, Johansson J, Niemelä S, Ollikainen A, Hirvonen MM, Piepponen P, et al. Mesolimbic dopamine release is linked to symptom severity in pathological gambling. Neuroimage. 2012;60:1992–9. https://doi.org/10.1016/j.neuroimage.2012.02.006.CrossRefPubMed

21.

Boileau I, Payer D, Chugani B, Lobo DS, Houle S, Wilson AA, et al. In vivo evidence for greater amphetamine-induced dopamine release in pathological gambling: a positron emission tomography study with [(11)C]-(+)-PHNO. Mol Psychiatry. 2014;19:1305–13. https://doi.org/10.1038/mp.2013.163.CrossRefPubMed

22.

Majuri J, Joutsa J, Johansson J, Voon V, Alakurtti K, Parkkola R, et al. Dopamine and opioid neurotransmission in behavioral addictions: a comparative PET study in pathological gambling and binge eating. Neuropsychopharmacology. 2017;42:1169–77. https://doi.org/10.1038/npp.2016.265.CrossRefPubMed

23.

Pettorruso M, Martinotti G, Cocciolillo F, De Risio L, Cinquino A, Di Nicola M, et al. Striatal presynaptic dopaminergic dysfunction in gambling disorder: a ¹²³I‐FP‐CIT SPECT study. Addict Biol. 2018. https://doi.org/10.1111/adb.12677.

24.

Hammes J, Theis H, Giehl K, Hoenig MC, Greuel A, Tittgemeyer M, et al. Dopamine metabolism of the nucleus accumbens and fronto-striatal connectivity modulate impulse control. Brain. 2019;142:733–43. https://doi.org/10.1093/brain/awz007.CrossRefPubMed

25.

Voon V, Mehta AR, Hallett M. Impulse control disorders in Parkinson’s disease: recent advances. Curr Opin Neurol. 2011;24:324–30. https://doi.org/10.1097/WCO.0b013e3283489687.CrossRefPubMedPubMedCentral

26.

Eklund A, Nichols TE, Knutsson H. Cluster failure: why fMRI inferences for spatial extent have inflated false-positive rates. Proc Natl Acad Sci U S A. 2016;113:7900–5. https://doi.org/10.1073/pnas.1602413113.CrossRefPubMedPubMedCentral

27.

Verger A, Klesse E, Chawki MB, Witjas T, Azulay JP, Eusebio A, et al. Brain PET substrate of impulse control disorders in Parkinson’s disease: a metabolic connectivity study. Hum Brain Mapp. 2018;39:3178–86. https://doi.org/10.1002/hbm.24068.CrossRefPubMed

Title: Molecular imaging of impulse control disorders in Parkinson’s disease
Authors: Joonas Majuri
Juho Joutsa
Publication date: 01-10-2019
Publisher: Springer Berlin Heidelberg
Keywords: Molecular Imaging
Positron Emission Tomography
Parkinson's Disease
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2019
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04459-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Molecular imaging of impulse control disorders in Parkinson’s disease

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 11/2019

Controls-based denoising, a new approach for medical image analysis, improves prediction of conversion to Alzheimer’s disease with FDG-PET

PET imaging of metabolic changes after neural stem cells and GABA progenitor cells transplantation in a rat model of temporal lobe epilepsy

Radiation-induced myocardial damage indicated by focal defect on 123I-MIBG SPECT

Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study

No differences in rest myocardial blood flow in stunned and hibernating myocardium: insights into the pathophysiology of ischemic cardiomyopathy

Effects of age, BMI and sex on the glial cell marker TSPO — a multicentre [11C]PBR28 HRRT PET study